These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37937851)

  • 1. Proton Pump Inhibitor Use and Complications of Cirrhosis Are Linked With Distinct Gut Microbial Bacteriophage and Eukaryotic Viral-Like Particle Signatures in Cirrhosis.
    Peña Rodríguez M; Fagan A; Sikaroodi M; Gillevet PM; Bajaj JS
    Clin Transl Gastroenterol; 2024 Feb; 15(2):e00659. PubMed ID: 37937851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites.
    Dam G; Vilstrup H; Watson H; Jepsen P
    Hepatology; 2016 Oct; 64(4):1265-72. PubMed ID: 27474889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis.
    Bajaj JS; Acharya C; Fagan A; White MB; Gavis E; Heuman DM; Hylemon PB; Fuchs M; Puri P; Schubert ML; Sanyal AJ; Sterling RK; Stravitz TR; Siddiqui MS; Luketic V; Lee H; Sikaroodi M; Gillevet PM
    Am J Gastroenterol; 2018 Aug; 113(8):1177-1186. PubMed ID: 29872220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of proton pump inhibitors on microbiota in chronic liver disease patients.
    Yamamoto K; Ishigami M; Honda T; Takeyama T; Ito T; Ishizu Y; Kuzuya T; Hayashi K; Goto H; Hirooka Y
    Hepatol Int; 2019 Mar; 13(2):234-244. PubMed ID: 30737678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis.
    Nardelli S; Gioia S; Ridola L; Farcomeni A; Merli M; Riggio O
    Hepatology; 2019 Aug; 70(2):640-649. PubMed ID: 30289992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
    Tsai CF; Chen MH; Wang YP; Chu CJ; Huang YH; Lin HC; Hou MC; Lee FY; Su TP; Lu CL
    Gastroenterology; 2017 Jan; 152(1):134-141. PubMed ID: 27639806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
    Saboo K; Shamsaddini A; Iyer MV; Hu C; Fagan A; Gavis EA; White MB; Fuchs M; Heuman DM; Sikaroodi M; Iyer RK; Gillevet PM; Bajaj JS
    J Hepatol; 2021 Jan; 74(1):80-88. PubMed ID: 32679299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Emulated Clinical Trial of Deprescribing Proton Pump Inhibitors in Patients With Cirrhosis.
    Tapper EB; Zhao Z; Parikh ND
    Am J Gastroenterol; 2024 Jan; 119(1):203-205. PubMed ID: 37561055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis.
    De Roza MA; Kai L; Kam JW; Chan YH; Kwek A; Ang TL; Hsiang JC
    World J Gastroenterol; 2019 Sep; 25(33):4933-4944. PubMed ID: 31543684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in gut virome are associated with cognitive function and minimal hepatic encephalopathy cross-sectionally and longitudinally in cirrhosis.
    Jinato T; Sikaroodi M; Fagan A; Sterling RK; Lee H; Puri P; Davis BC; Fuchs M; Gavis E; Gillevet PM; Bajaj JS
    Gut Microbes; 2023 Dec; 15(2):2288168. PubMed ID: 38010871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton pump inhibitors increase the severity of hepatic encephalopathy in cirrhotic patients.
    Fasullo M; Rau P; Liu DQ; Holzwanger E; Mathew JP; Guilarte-Walker Y; Szabo G
    World J Hepatol; 2019 Jun; 11(6):522-530. PubMed ID: 31293720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton Pump Inhibitor Therapy and Hepatic Encephalopathy Risk in Cirrhotic Patients: A Systematic Review with Meta-analysis.
    Shi D; Zhou Z; Dai Y; Pan X; Cao Q
    Clin Drug Investig; 2019 Sep; 39(9):847-856. PubMed ID: 31183628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.
    Mandorfer M; Bota S; Schwabl P; Bucsics T; Pfisterer N; Summereder C; Hagmann M; Blacky A; Ferlitsch A; Sieghart W; Trauner M; Peck-Radosavljevic M; Reiberger T
    PLoS One; 2014; 9(11):e110503. PubMed ID: 25369194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients.
    Wellhöner F; Döscher N; Tergast TL; Vital M; Plumeier I; Kahl S; Potthoff A; Manns MP; Maasoumy B; Wedemeyer H; Cornberg M; Pieper DH; Heidrich B
    Scand J Gastroenterol; 2019 Aug; 54(8):1033-1041. PubMed ID: 31361979
    [No Abstract]   [Full Text] [Related]  

  • 15. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
    Bajaj JS; Sikaroodi M; Shamsaddini A; Henseler Z; Santiago-Rodriguez T; Acharya C; Fagan A; Hylemon PB; Fuchs M; Gavis E; Ward T; Knights D; Gillevet PM
    Gut; 2021 Jun; 70(6):1162-1173. PubMed ID: 32998876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors: A multicenter retrospective study in Japan.
    Sakamaki A; Kamimura K; Yokoo T; Osaki A; Yoshikawa S; Arao Y; Setsu T; Kamimura H; Waguri N; Takeuchi M; Funakoshi K; Terai S
    Medicine (Baltimore); 2021 Aug; 100(32):e26902. PubMed ID: 34397919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosis.
    Bajaj JS; Shamsaddini A; Acharya C; Fagan A; Sikaroodi M; Gavis E; McGeorge S; Khoruts A; Fuchs M; Sterling RK; Lee H; Gillevet PM
    Gut Microbes; 2021; 13(1):1993584. PubMed ID: 34743650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial.
    Wehmeyer MH; Horvatits T; Buchholz A; Krause L; Walter S; Zapf A; Lohse AW; Kluwe J;
    Trials; 2022 Apr; 23(1):302. PubMed ID: 35414106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites.
    de Vos M; De Vroey B; Garcia BG; Roy C; Kidd F; Henrion J; Deltenre P
    Liver Int; 2013 Oct; 33(9):1316-23. PubMed ID: 23730823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation Between Proton Pump Inhibitors and the Complications of Liver Cirrhosis: A Systematic Review and Meta-Analysis.
    Hwang SJ; Lee DH; Koh SJ; Kim JW; Park HS; Kim BG; Lee KL
    Turk J Gastroenterol; 2022 Jan; 33(1):44-52. PubMed ID: 35040787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.